Can We Efficiently Target HDAC in Cancer?

Tobias Kiesslich; Daniel Neureiter

doi:10.3390/cancers14164058

Can We Efficiently Target HDAC in Cancer?

Cancers (Basel). 2022 Aug 22;14(16):4058. doi: 10.3390/cancers14164058.

Authors

Tobias Kiesslich^{1

2}, Daniel Neureiter^{3

4}

Affiliations

¹ Center for Physiology, Pathophysiology and Biophysics-Salzburg and Nuremberg, Institute for Physiology and Pathophysiology-Salzburg, Paracelsus Medical University, Strubergasse 22, 5020 Salzburg, Austria.
² Department of Internal Medicine I, University Clinics Salzburg, Paracelsus Medical University, Müllner Hauptstrasse 48, 5020 Salzburg, Austria.
³ Institute of Pathology, University Clinics Salzburg, Paracelsus Medical University, Müllner Hauptstrasse 48, 5020 Salzburg, Austria.
⁴ Cancer Cluster Salzburg, 5020 Salzburg, Austria.

Abstract

According to the hallmarks of cancer, typical processes of human cancer initiation, progression, and metastasis are essentially influenced by pathologic epigenetic deregulations via DNA methylation and/or histone modification [...].

Publication types

Editorial

Grants and funding

This research received no external funding.